ParkinsonCanadaV1, PascalFrancis, Curation, bibRecord, 000149

Role of serotonin2C receptors in the control of brain dopaminergic function

Identifieur interne : 000149 ( PascalFrancis/Curation ); précédent : 000148; suivant : 000150

Role of serotonin2C receptors in the control of brain dopaminergic function

Auteurs : Vincenzo Di Matteo [Italie] ; Marisa Cacchio [Italie] ; Camillo Di Giulio [Italie] ; Ennio Esposito [Italie]

Source :

Pharmacology, biochemistry and behavior [ 0091-3057 ] ; 2002.

RBID : Pascal:02-0355643

Descripteurs français

Pascal (Inist)
- Récepteur sérotoninergique 5-HT2C, Rat, Homme, Etat dépressif, In vitro, In vivo, Schizophrénie, Parkinson maladie, Dépendance, Article synthèse, Sérotonine, Voie dopaminergique, Encéphale, Dopamine, Antagoniste, Agoniste, Système nerveux central, Aire tegmentaire ventrale, Locus niger, Voie nigrostriatale, Neuroleptique, Psychotrope, Animal, Voie mésolimbique, Antidépresseur.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- 5-HT2C serotonin receptor, Agonist, Animal, Antagonist, Antidepressant agent, Brain (vertebrata), Central nervous system, Dependence, Depression, Dopamine, Dopaminergic pathway, Human, In vitro, In vivo, Locus niger, Mesolimbic pathway, Neuroleptic, Nigrostriatal pathway, Parkinson disease, Psychotropic, Rat, Review, Schizophrenia, Serotonin, Ventral tegmental area.

Abstract

There is substantial evidence that the functional status of mesocorticolimbic dopaminergic (DA) system originating in the ventral tegmental area (VTA) is under a phasic and tonic inhibitory control by the serotonergic system, which acts by stimulating serotonin_2C (5-HT_2C) receptor subtypes. This assertion is based upon a number of electrophysiological and biochemical data showing that 5-HT_2C receptor agonists decrease, while 5-HT_2C receptor antagonists enhance mesocorticolimbic DA function. On the other hand, it does not seem that 5-HT_2C receptors play a relevant role in the control of nigrostriatal DA system originating in the substantia nigra pars compacta (SNc). The authors of this article review the most relevant data regarding the role of 5-HT_2C receptors in the control of brain DA function and underline the importance of this subject in the search of new therapies for neuropsychiatric disorders such as depression, schizophrenia, drug addiction, and Parkinson's disease.

A01	`01`	`1`		`@0 0091-3057`
A02	`01`			`@0 PBBHAU`
A03		`1`		`@0 Pharmacol. biochem. behav.`
A05				`@2 71`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Role of serotonin_2C receptors in the control of brain dopaminergic function`
A09	`01`	`1`	`ENG`	`@1 Serotonin: pharmacology, biochemistry and behavior`
A11	`01`	`1`		`@1 DI MATTEO (Vincenzo)`
A11	`02`	`1`		`@1 CACCHIO (Marisa)`
A11	`03`	`1`		`@1 DI GIULIO (Camillo)`
A11	`04`	`1`		`@1 ESPOSITO (Ennio)`
A12	`01`	`1`		`@1 HIGGINS (Guy A.) @9 ed.`
A12	`02`	`1`		`@1 FLETCHER (Paul J.) @9 ed.`
A14	`01`			`@1 Istituto di Ricerche Farmacologiche "Mario Negri", Consorzio "Mario Negri" Sud @2 66030 Santa Maria Imbaro, Chieti @3 ITA @Z 1 aut. @Z 4 aut.`
A14	`02`			`@1 Department of Biomedical Sciences, Università "G. D'Annunzio" @2 Chieti @3 ITA @Z 2 aut. @Z 3 aut.`
A15	`01`			`@1 Pharma Research Basel Neuroscience, Bau 72/150, F. Hoffmann-La Roche Ltd. @2 4070 Basel @3 CHE @Z 1 aut.`
A15	`02`			`@1 Schering-Plough Research Institute, 2015 Galloping Hill Road @2 Kenilworth, NJ 07033-1300 @3 USA @Z 1 aut.`
A15	`03`			`@1 Centre for Addiction and Mental Health, 250 College St. Toronto @2 Toronto, Ontario, M5T 1R8 @3 CAN @Z 2 aut.`
A15	`04`			`@1 Departments of Psychiatry and Psychology, University of Toronto @2 Toronto, Ontario @3 CAN @Z 2 aut.`
A20				`@1 727-734`
A21				`@1 2002`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 16578 @5 354000100614230190`
A44				`@0 0000 @1 © 2002 INIST-CNRS. All rights reserved.`
A45				`@0 1 p.1/4`
A47	`01`	`1`		`@0 02-0355643`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Pharmacology, biochemistry and behavior`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 There is substantial evidence that the functional status of mesocorticolimbic dopaminergic (DA) system originating in the ventral tegmental area (VTA) is under a phasic and tonic inhibitory control by the serotonergic system, which acts by stimulating serotonin_2C (5-HT_2C) receptor subtypes. This assertion is based upon a number of electrophysiological and biochemical data showing that 5-HT_2C receptor agonists decrease, while 5-HT_2C receptor antagonists enhance mesocorticolimbic DA function. On the other hand, it does not seem that 5-HT_2C receptors play a relevant role in the control of nigrostriatal DA system originating in the substantia nigra pars compacta (SNc). The authors of this article review the most relevant data regarding the role of 5-HT_2C receptors in the control of brain DA function and underline the importance of this subject in the search of new therapies for neuropsychiatric disorders such as depression, schizophrenia, drug addiction, and Parkinson's disease.
C02	`01`	`X`		`@0 002B02B09C`
C02	`02`	`X`		`@0 002A04F03B`
C03	`01`	`X`	`FRE`	`@0 Récepteur sérotoninergique 5-HT2C @5 01`
C03	`01`	`X`	`ENG`	`@0 5-HT2C serotonin receptor @5 01`
C03	`01`	`X`	`SPA`	`@0 Receptor serotoninérgico 5-HT2C @5 01`
C03	`02`	`X`	`FRE`	`@0 Rat @5 02`
C03	`02`	`X`	`ENG`	`@0 Rat @5 02`
C03	`02`	`X`	`SPA`	`@0 Rata @5 02`
C03	`03`	`X`	`FRE`	`@0 Homme @5 03`
C03	`03`	`X`	`ENG`	`@0 Human @5 03`
C03	`03`	`X`	`SPA`	`@0 Hombre @5 03`
C03	`04`	`X`	`FRE`	`@0 Etat dépressif @5 04`
C03	`04`	`X`	`ENG`	`@0 Depression @5 04`
C03	`04`	`X`	`SPA`	`@0 Estado depresivo @5 04`
C03	`05`	`X`	`FRE`	`@0 In vitro @5 05`
C03	`05`	`X`	`ENG`	`@0 In vitro @5 05`
C03	`05`	`X`	`SPA`	`@0 In vitro @5 05`
C03	`06`	`X`	`FRE`	`@0 In vivo @5 06`
C03	`06`	`X`	`ENG`	`@0 In vivo @5 06`
C03	`06`	`X`	`SPA`	`@0 In vivo @5 06`
C03	`07`	`X`	`FRE`	`@0 Schizophrénie @5 07`
C03	`07`	`X`	`ENG`	`@0 Schizophrenia @5 07`
C03	`07`	`X`	`SPA`	`@0 Esquizofrenia @5 07`
C03	`08`	`X`	`FRE`	`@0 Parkinson maladie @5 10`
C03	`08`	`X`	`ENG`	`@0 Parkinson disease @5 10`
C03	`08`	`X`	`SPA`	`@0 Parkinson enfermedad @5 10`
C03	`09`	`X`	`FRE`	`@0 Dépendance @5 11`
C03	`09`	`X`	`ENG`	`@0 Dependence @5 11`
C03	`09`	`X`	`SPA`	`@0 Dependencia @5 11`
C03	`10`	`X`	`FRE`	`@0 Article synthèse @5 12`
C03	`10`	`X`	`ENG`	`@0 Review @5 12`
C03	`10`	`X`	`SPA`	`@0 Artículo síntesis @5 12`
C03	`11`	`X`	`FRE`	`@0 Sérotonine @2 NK @2 FR @5 13`
C03	`11`	`X`	`ENG`	`@0 Serotonin @2 NK @2 FR @5 13`
C03	`11`	`X`	`SPA`	`@0 Serotonina @2 NK @2 FR @5 13`
C03	`12`	`X`	`FRE`	`@0 Voie dopaminergique @5 14`
C03	`12`	`X`	`ENG`	`@0 Dopaminergic pathway @5 14`
C03	`12`	`X`	`SPA`	`@0 Vía dopaminérgica @5 14`
C03	`13`	`X`	`FRE`	`@0 Encéphale @5 15`
C03	`13`	`X`	`ENG`	`@0 Brain (vertebrata) @5 15`
C03	`13`	`X`	`SPA`	`@0 Encéfalo @5 15`
C03	`14`	`X`	`FRE`	`@0 Dopamine @2 NK @2 FR @5 16`
C03	`14`	`X`	`ENG`	`@0 Dopamine @2 NK @2 FR @5 16`
C03	`14`	`X`	`SPA`	`@0 Dopamina @2 NK @2 FR @5 16`
C03	`15`	`X`	`FRE`	`@0 Antagoniste @5 17`
C03	`15`	`X`	`ENG`	`@0 Antagonist @5 17`
C03	`15`	`X`	`SPA`	`@0 Antagonista @5 17`
C03	`16`	`X`	`FRE`	`@0 Agoniste @5 18`
C03	`16`	`X`	`ENG`	`@0 Agonist @5 18`
C03	`16`	`X`	`SPA`	`@0 Agonista @5 18`
C03	`17`	`X`	`FRE`	`@0 Système nerveux central @5 19`
C03	`17`	`X`	`ENG`	`@0 Central nervous system @5 19`
C03	`17`	`X`	`SPA`	`@0 Sistema nervioso central @5 19`
C03	`18`	`X`	`FRE`	`@0 Aire tegmentaire ventrale @5 20`
C03	`18`	`X`	`ENG`	`@0 Ventral tegmental area @5 20`
C03	`18`	`X`	`SPA`	`@0 Area tegmental ventral @5 20`
C03	`19`	`X`	`FRE`	`@0 Locus niger @5 21`
C03	`19`	`X`	`ENG`	`@0 Locus niger @5 21`
C03	`19`	`X`	`SPA`	`@0 Locus níger @5 21`
C03	`20`	`X`	`FRE`	`@0 Voie nigrostriatale @5 22`
C03	`20`	`X`	`ENG`	`@0 Nigrostriatal pathway @5 22`
C03	`20`	`X`	`SPA`	`@0 Vía nigroestriatal @5 22`
C03	`21`	`X`	`FRE`	`@0 Neuroleptique @5 23`
C03	`21`	`X`	`ENG`	`@0 Neuroleptic @5 23`
C03	`21`	`X`	`SPA`	`@0 Neuroléptico @5 23`
C03	`22`	`X`	`FRE`	`@0 Psychotrope @2 FX @5 24`
C03	`22`	`X`	`ENG`	`@0 Psychotropic @2 FX @5 24`
C03	`22`	`X`	`SPA`	`@0 Psicotropo @2 FX @5 24`
C03	`23`	`X`	`FRE`	`@0 Animal @5 35`
C03	`23`	`X`	`ENG`	`@0 Animal @5 35`
C03	`23`	`X`	`SPA`	`@0 Animal @5 35`
C03	`24`	`X`	`FRE`	`@0 Voie mésolimbique @5 78`
C03	`24`	`X`	`ENG`	`@0 Mesolimbic pathway @5 78`
C03	`24`	`X`	`SPA`	`@0 Vía mesolímbica @5 78`
C03	`25`	`X`	`FRE`	`@0 Antidépresseur @5 79`
C03	`25`	`X`	`ENG`	`@0 Antidepressant agent @5 79`
C03	`25`	`X`	`SPA`	`@0 Antidepresor @5 79`
C07	`01`	`X`	`FRE`	`@0 Rodentia @2 NS`
C07	`01`	`X`	`ENG`	`@0 Rodentia @2 NS`
C07	`01`	`X`	`SPA`	`@0 Rodentia @2 NS`
C07	`02`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`02`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`02`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`03`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`03`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`03`	`X`	`SPA`	`@0 Vertebrata @2 NS`
C07	`04`	`X`	`FRE`	`@0 Catécholamine @5 37`
C07	`04`	`X`	`ENG`	`@0 Catecholamine @5 37`
C07	`04`	`X`	`SPA`	`@0 Catecolamina @5 37`
C07	`05`	`X`	`FRE`	`@0 Trouble humeur @5 45`
C07	`05`	`X`	`ENG`	`@0 Mood disorder @5 45`
C07	`05`	`X`	`SPA`	`@0 Trastorno humor @5 45`
C07	`06`	`X`	`FRE`	`@0 Psychose @5 53`
C07	`06`	`X`	`ENG`	`@0 Psychosis @5 53`
C07	`06`	`X`	`SPA`	`@0 Psicosis @5 53`
C07	`07`	`X`	`FRE`	`@0 Système nerveux pathologie @5 61`
C07	`07`	`X`	`ENG`	`@0 Nervous system diseases @5 61`
C07	`07`	`X`	`SPA`	`@0 Sistema nervioso patología @5 61`
C07	`08`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 62`
C07	`08`	`X`	`ENG`	`@0 Central nervous system disease @5 62`
C07	`08`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 62`
C07	`09`	`X`	`FRE`	`@0 Encéphale pathologie @5 63`
C07	`09`	`X`	`ENG`	`@0 Cerebral disorder @5 63`
C07	`09`	`X`	`SPA`	`@0 Encéfalo patología @5 63`
C07	`10`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 64`
C07	`10`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 64`
C07	`10`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 64`
C07	`11`	`X`	`FRE`	`@0 Maladie dégénérative @5 65`
C07	`11`	`X`	`ENG`	`@0 Degenerative disease @5 65`
C07	`11`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 65`
N21				`@1 196`
N82				`@1 PSI`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000B74

Links to Exploration step

Pascal:02-0355643

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Role of serotonin<sub>2C</sub>
 receptors in the control of brain dopaminergic function</title>
<author><name sortKey="Di Matteo, Vincenzo" sort="Di Matteo, Vincenzo" uniqKey="Di Matteo V" first="Vincenzo" last="Di Matteo">Vincenzo Di Matteo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Istituto di Ricerche Farmacologiche "Mario Negri", Consorzio "Mario Negri" Sud</s1>
<s2>66030 Santa Maria Imbaro, Chieti</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Cacchio, Marisa" sort="Cacchio, Marisa" uniqKey="Cacchio M" first="Marisa" last="Cacchio">Marisa Cacchio</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Biomedical Sciences, Università "G. D'Annunzio"</s1>
<s2>Chieti</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Di Giulio, Camillo" sort="Di Giulio, Camillo" uniqKey="Di Giulio C" first="Camillo" last="Di Giulio">Camillo Di Giulio</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Biomedical Sciences, Università "G. D'Annunzio"</s1>
<s2>Chieti</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Esposito, Ennio" sort="Esposito, Ennio" uniqKey="Esposito E" first="Ennio" last="Esposito">Ennio Esposito</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Istituto di Ricerche Farmacologiche "Mario Negri", Consorzio "Mario Negri" Sud</s1>
<s2>66030 Santa Maria Imbaro, Chieti</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">02-0355643</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 02-0355643 INIST</idno>
<idno type="RBID">Pascal:02-0355643</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B74</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000149</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Role of serotonin<sub>2C</sub>
 receptors in the control of brain dopaminergic function</title>
<author><name sortKey="Di Matteo, Vincenzo" sort="Di Matteo, Vincenzo" uniqKey="Di Matteo V" first="Vincenzo" last="Di Matteo">Vincenzo Di Matteo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Istituto di Ricerche Farmacologiche "Mario Negri", Consorzio "Mario Negri" Sud</s1>
<s2>66030 Santa Maria Imbaro, Chieti</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Cacchio, Marisa" sort="Cacchio, Marisa" uniqKey="Cacchio M" first="Marisa" last="Cacchio">Marisa Cacchio</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Biomedical Sciences, Università "G. D'Annunzio"</s1>
<s2>Chieti</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Di Giulio, Camillo" sort="Di Giulio, Camillo" uniqKey="Di Giulio C" first="Camillo" last="Di Giulio">Camillo Di Giulio</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Biomedical Sciences, Università "G. D'Annunzio"</s1>
<s2>Chieti</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Esposito, Ennio" sort="Esposito, Ennio" uniqKey="Esposito E" first="Ennio" last="Esposito">Ennio Esposito</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Istituto di Ricerche Farmacologiche "Mario Negri", Consorzio "Mario Negri" Sud</s1>
<s2>66030 Santa Maria Imbaro, Chieti</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Pharmacology, biochemistry and behavior</title>
<title level="j" type="abbreviated">Pharmacol. biochem. behav.</title>
<idno type="ISSN">0091-3057</idno>
<imprint><date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Pharmacology, biochemistry and behavior</title>
<title level="j" type="abbreviated">Pharmacol. biochem. behav.</title>
<idno type="ISSN">0091-3057</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>5-HT2C serotonin receptor</term>
<term>Agonist</term>
<term>Animal</term>
<term>Antagonist</term>
<term>Antidepressant agent</term>
<term>Brain (vertebrata)</term>
<term>Central nervous system</term>
<term>Dependence</term>
<term>Depression</term>
<term>Dopamine</term>
<term>Dopaminergic pathway</term>
<term>Human</term>
<term>In vitro</term>
<term>In vivo</term>
<term>Locus niger</term>
<term>Mesolimbic pathway</term>
<term>Neuroleptic</term>
<term>Nigrostriatal pathway</term>
<term>Parkinson disease</term>
<term>Psychotropic</term>
<term>Rat</term>
<term>Review</term>
<term>Schizophrenia</term>
<term>Serotonin</term>
<term>Ventral tegmental area</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Récepteur sérotoninergique 5-HT2C</term>
<term>Rat</term>
<term>Homme</term>
<term>Etat dépressif</term>
<term>In vitro</term>
<term>In vivo</term>
<term>Schizophrénie</term>
<term>Parkinson maladie</term>
<term>Dépendance</term>
<term>Article synthèse</term>
<term>Sérotonine</term>
<term>Voie dopaminergique</term>
<term>Encéphale</term>
<term>Dopamine</term>
<term>Antagoniste</term>
<term>Agoniste</term>
<term>Système nerveux central</term>
<term>Aire tegmentaire ventrale</term>
<term>Locus niger</term>
<term>Voie nigrostriatale</term>
<term>Neuroleptique</term>
<term>Psychotrope</term>
<term>Animal</term>
<term>Voie mésolimbique</term>
<term>Antidépresseur</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">There is substantial evidence that the functional status of mesocorticolimbic dopaminergic (DA) system originating in the ventral tegmental area (VTA) is under a phasic and tonic inhibitory control by the serotonergic system, which acts by stimulating serotonin<sub>2C</sub>
 (5-HT<sub>2C</sub>
) receptor subtypes. This assertion is based upon a number of electrophysiological and biochemical data showing that 5-HT<sub>2C</sub>
 receptor agonists decrease, while 5-HT<sub>2C</sub>
 receptor antagonists enhance mesocorticolimbic DA function. On the other hand, it does not seem that 5-HT<sub>2C</sub>
 receptors play a relevant role in the control of nigrostriatal DA system originating in the substantia nigra pars compacta (SNc). The authors of this article review the most relevant data regarding the role of 5-HT<sub>2C</sub>
 receptors in the control of brain DA function and underline the importance of this subject in the search of new therapies for neuropsychiatric disorders such as depression, schizophrenia, drug addiction, and Parkinson's disease.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0091-3057</s0>
</fA01>
<fA02 i1="01"><s0>PBBHAU</s0>
</fA02>
<fA03 i2="1"><s0>Pharmacol. biochem. behav.</s0>
</fA03>
<fA05><s2>71</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Role of serotonin<sub>2C</sub>
 receptors in the control of brain dopaminergic function</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Serotonin: pharmacology, biochemistry and behavior</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>DI MATTEO (Vincenzo)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>CACCHIO (Marisa)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>DI GIULIO (Camillo)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>ESPOSITO (Ennio)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>HIGGINS (Guy A.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="02" i2="1"><s1>FLETCHER (Paul J.)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>Istituto di Ricerche Farmacologiche "Mario Negri", Consorzio "Mario Negri" Sud</s1>
<s2>66030 Santa Maria Imbaro, Chieti</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Biomedical Sciences, Università "G. D'Annunzio"</s1>
<s2>Chieti</s2>
<s3>ITA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Pharma Research Basel Neuroscience, Bau 72/150, F. Hoffmann-La Roche Ltd.</s1>
<s2>4070 Basel</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="02"><s1>Schering-Plough Research Institute, 2015 Galloping Hill Road</s1>
<s2>Kenilworth, NJ 07033-1300</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="03"><s1>Centre for Addiction and Mental Health, 250 College St. Toronto</s1>
<s2>Toronto, Ontario, M5T 1R8</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</fA15>
<fA15 i1="04"><s1>Departments of Psychiatry and Psychology, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</fA15>
<fA20><s1>727-734</s1>
</fA20>
<fA21><s1>2002</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>16578</s2>
<s5>354000100614230190</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2002 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1 p.1/4</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>02-0355643</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Pharmacology, biochemistry and behavior</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>There is substantial evidence that the functional status of mesocorticolimbic dopaminergic (DA) system originating in the ventral tegmental area (VTA) is under a phasic and tonic inhibitory control by the serotonergic system, which acts by stimulating serotonin<sub>2C</sub>
 (5-HT<sub>2C</sub>
) receptor subtypes. This assertion is based upon a number of electrophysiological and biochemical data showing that 5-HT<sub>2C</sub>
 receptor agonists decrease, while 5-HT<sub>2C</sub>
 receptor antagonists enhance mesocorticolimbic DA function. On the other hand, it does not seem that 5-HT<sub>2C</sub>
 receptors play a relevant role in the control of nigrostriatal DA system originating in the substantia nigra pars compacta (SNc). The authors of this article review the most relevant data regarding the role of 5-HT<sub>2C</sub>
 receptors in the control of brain DA function and underline the importance of this subject in the search of new therapies for neuropsychiatric disorders such as depression, schizophrenia, drug addiction, and Parkinson's disease.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B09C</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002A04F03B</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Récepteur sérotoninergique 5-HT2C</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>5-HT2C serotonin receptor</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Receptor serotoninérgico 5-HT2C</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Rat</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Rat</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Rata</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Homme</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Human</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Hombre</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Etat dépressif</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Depression</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Estado depresivo</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>In vitro</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>In vitro</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>In vitro</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>In vivo</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>In vivo</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>In vivo</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Schizophrénie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Schizophrenia</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Esquizofrenia</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Dépendance</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Dependence</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Dependencia</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Review</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Sérotonine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Serotonin</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Serotonina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Voie dopaminergique</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Dopaminergic pathway</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Vía dopaminérgica</s0>
<s5>14</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Encéphale</s0>
<s5>15</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Brain (vertebrata)</s0>
<s5>15</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Encéfalo</s0>
<s5>15</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>16</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>16</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>16</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Antagoniste</s0>
<s5>17</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Antagonist</s0>
<s5>17</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Antagonista</s0>
<s5>17</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>18</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Agonist</s0>
<s5>18</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Agonista</s0>
<s5>18</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>19</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>19</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>19</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Aire tegmentaire ventrale</s0>
<s5>20</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Ventral tegmental area</s0>
<s5>20</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Area tegmental ventral</s0>
<s5>20</s5>
</fC03>
<fC03 i1="19" i2="X" l="FRE"><s0>Locus niger</s0>
<s5>21</s5>
</fC03>
<fC03 i1="19" i2="X" l="ENG"><s0>Locus niger</s0>
<s5>21</s5>
</fC03>
<fC03 i1="19" i2="X" l="SPA"><s0>Locus níger</s0>
<s5>21</s5>
</fC03>
<fC03 i1="20" i2="X" l="FRE"><s0>Voie nigrostriatale</s0>
<s5>22</s5>
</fC03>
<fC03 i1="20" i2="X" l="ENG"><s0>Nigrostriatal pathway</s0>
<s5>22</s5>
</fC03>
<fC03 i1="20" i2="X" l="SPA"><s0>Vía nigroestriatal</s0>
<s5>22</s5>
</fC03>
<fC03 i1="21" i2="X" l="FRE"><s0>Neuroleptique</s0>
<s5>23</s5>
</fC03>
<fC03 i1="21" i2="X" l="ENG"><s0>Neuroleptic</s0>
<s5>23</s5>
</fC03>
<fC03 i1="21" i2="X" l="SPA"><s0>Neuroléptico</s0>
<s5>23</s5>
</fC03>
<fC03 i1="22" i2="X" l="FRE"><s0>Psychotrope</s0>
<s2>FX</s2>
<s5>24</s5>
</fC03>
<fC03 i1="22" i2="X" l="ENG"><s0>Psychotropic</s0>
<s2>FX</s2>
<s5>24</s5>
</fC03>
<fC03 i1="22" i2="X" l="SPA"><s0>Psicotropo</s0>
<s2>FX</s2>
<s5>24</s5>
</fC03>
<fC03 i1="23" i2="X" l="FRE"><s0>Animal</s0>
<s5>35</s5>
</fC03>
<fC03 i1="23" i2="X" l="ENG"><s0>Animal</s0>
<s5>35</s5>
</fC03>
<fC03 i1="23" i2="X" l="SPA"><s0>Animal</s0>
<s5>35</s5>
</fC03>
<fC03 i1="24" i2="X" l="FRE"><s0>Voie mésolimbique</s0>
<s5>78</s5>
</fC03>
<fC03 i1="24" i2="X" l="ENG"><s0>Mesolimbic pathway</s0>
<s5>78</s5>
</fC03>
<fC03 i1="24" i2="X" l="SPA"><s0>Vía mesolímbica</s0>
<s5>78</s5>
</fC03>
<fC03 i1="25" i2="X" l="FRE"><s0>Antidépresseur</s0>
<s5>79</s5>
</fC03>
<fC03 i1="25" i2="X" l="ENG"><s0>Antidepressant agent</s0>
<s5>79</s5>
</fC03>
<fC03 i1="25" i2="X" l="SPA"><s0>Antidepresor</s0>
<s5>79</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Trouble humeur</s0>
<s5>45</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Mood disorder</s0>
<s5>45</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Trastorno humor</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Psychose</s0>
<s5>53</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Psychosis</s0>
<s5>53</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Psicosis</s0>
<s5>53</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>61</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>61</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>61</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>62</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>62</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>62</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>63</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>63</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>63</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>64</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>64</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>64</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>65</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>65</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>65</s5>
</fC07>
<fN21><s1>196</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000149 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000149 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:02-0355643
   |texte=   Role of serotonin2C receptors in the control of brain dopaminergic function
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Role of serotonin2C receptors in the control of brain dopaminergic function

Role of serotonin2C receptors in the control of brain dopaminergic function

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri